Theratechnologies other research news

TH.B presented in vitro data on a potential gene therapy at the International Conference on AIDS in Vancouver. The company is using a modified Vpr protein targeted at mature HIV virions, in order to affect their structural organization and/or functional integrity.

Cell lines expressing the chimeric Vpr proteins weren't infected with HIV after 20 days, as measured by reverse transcriptase activity or p24 antigen. In contrast, the control cell line was fully infected after five days. ...